Skip to main content
    E

    Enlivex Therapeutics Ltd (ENLV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.10
    -0.09 (-7.56%)

    Market Cap: $1.82M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Enlivex Therapeutics Ltd (ENLV) Financials: Revenue, Profit and Cash Flow

    Updated Sep 4, 2026. Financial statements from company filings, amounts in US dollars.

    Enlivex Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was $1.24B, operating cash flow was -$10.42M and free cash flow was -$10.48M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of $1.89B.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $15.00M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$2.28MN/A-12.6%-429.7%-519.3%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$0$2.28M$0$0$0$0
    Cost of revenue$332.00K$545.00K$835.00K$777.00K$546.00K$286.00K$297.00K$121.00K$12.00K$25.00K
    Gross profit-$332.00K-$545.00K-$835.00K-$777.00K-$546.00K-$286.00K-$297.00K-$121.00K-$12.00K-$25.00K
    Research and development$8.92M$10.13M$19.23M$18.69M$12.88M$6.09M$5.72M$4.13M$2.52M$8.88M
    Operating income-$15.00M-$15.54M-$29.39M-$25.80M-$19.29M-$9.79M-$8.62M-$5.30M-$5.85M-$13.95M
    Net income$1.24B-$15.01M-$29.07M-$31.06M-$14.47M-$11.82M-$9.38M-$4.24M-$5.95M-$16.02M
    EBITDA-$14.67M-$14.47M-$28.22M-$25.02M-$18.74M-$9.50M-$8.41M-$5.18MN/A-$13.92M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Gross profit-$57.00KN/A-$76.00K-$81.00K-$85.00K-$90.00K-$36.00K-$161.00K-$160.00K-$188.00K-$200.00K-$214.00K
    Operating income-$4.23M-$7.91M-$5.86M-$2.56M-$3.08M-$3.53M-$5.63M-$3.12M-$2.99M-$3.95M-$6.09M-$5.63M
    Net income$1.89B$974.52M$1.24B-$2.21M-$1.87M-$3.45M-$5.18M-$2.60M-$3.10M-$4.14M-$9.10M-$5.96M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $258.00K by $1.75M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$2.33B$27.69M$36.83M$67.64M$95.15M$40.36M$17.56M$11.03M$3.62M$10.63M
    Current assets$1.74B$25.99M$33.76M$52.33M$86.44M$38.12M$16.42M$10.28M$3.62M$10.54M
    Cash and equivalents$2.01M$3.30M$813.00K$49.95M$11.20M$5.67M$3.95M$9.74M$3.53M$6.87M
    Total liabilities$392.05M$4.10M$6.75M$10.80M$10.11M$4.87M$6.28M$1.33M$460.00K$1.93M
    Short-term debt$258.00K$235.00K$346.00K$653.00K$617.00K$203.00K$123.00KN/AN/AN/A
    Shareholder equity$1.93B$23.59M$30.08M$56.84M$85.04M$35.49M$11.28M$9.71M$3.16M$8.70M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$4.90BN/A$2.33B$20.94M$22.60M$24.04M$27.69M$29.80M$31.90M$31.05M$36.83M$46.94M
    Total liabilities$1.00B-$1.93B$392.05M$3.46M$3.54M$3.41M$4.10M$3.21M$3.34M$4.20M$6.75M$8.16M
    Cash and equivalents$5.52MN/A$2.01M$4.20M$1.89M$2.05M$3.30M$2.77M$3.75M$2.03M$926.00K$1.97M
    Shareholder equity$3.90B$1.93B$1.93B$17.48M$19.05M$20.63M$23.59M$26.59M$28.56M$26.85M$30.08M$38.78M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$10.42M-$13.01M-$23.52M-$23.95M-$17.54M-$11.01M-$7.04M-$3.16M-$6.35M-$15.49M
    Capital expenditures$68.00K$103.00K$236.00K$8.12M$1.63M$1.02M$193.00K$461.00K$2.00K$18.00K
    Free cash flow-$10.48M-$13.11M-$23.76M-$32.08M-$19.17M-$12.03M-$7.23M-$3.62M-$6.35M-$15.50M
    Investing cash flow-$1.32M$9.06M-$25.97M$62.52M-$38.41M-$20.98M-$6.36M-$533.00K$3.01M$8.98M
    Financing cash flow$10.38M$6.45M$360.00K$150.00K$60.98M$33.08M$8.31M$5.19M$8.05M$6.09M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$5.47M-$5.47M-$2.90M-$1.97M-$1.20M-$4.62M-$4.08M-$2.62M-$1.80M-$4.51M-$5.03M-$5.44M
    Capital expenditures$4.50K$4.50K$9.38K$23.55K$7.00K$32.00K$35.00K$9.00K$16.00K$43.00KN/A$29.00K
    Free cash flow-$5.47M-$5.47M-$2.91M-$1.99M-$1.21M-$4.66M-$4.12M-$2.63M-$1.81M-$4.55MN/A-$5.47M
    Last 12 quarters

    Frequently Asked Questions About ENLV

    What is Enlivex Therapeutics' annual revenue?

    Enlivex Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Enlivex Therapeutics profitable?

    Yes. Enlivex Therapeutics reported net income of $1.24B for the fiscal year ended Dec 31, 2025.

    How much free cash flow does ENLV generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.42M minus capital expenditures of $68.00K produced free cash flow of -$10.48M.

    How much debt does Enlivex Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $258.00K and cash and equivalents of $2.01M.